46 patents
Page 3 of 3
Utility
Use of a Ppar-delta Agonist for Reducing Loss of Muscle Strength, Muscle Mass, or Type I Muscle Fibers In an Immobilized Limb
12 Feb 20
The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
Maria Carmen VALCARCE LOPEZ, Eliot OHLSTEIN
Filed: 21 Oct 19
Utility
Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof
15 Jan 20
The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators.
Otis Clinton Attucks
Filed: 24 Sep 19
Utility
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
11 Nov 19
Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein.
Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
Filed: 19 Nov 17
Utility
Tricyclic Compounds As Modulators of Tnf-alpha Synthesis and As PDE4 Inhibitors
6 Nov 19
The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4 including, but not limited to, allergic rhinitis.
Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
Filed: 9 Jul 19
Utility
Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
4 Nov 19
The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators.
Otis Clinton Attucks
Filed: 12 Nov 18
Utility
Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
28 Oct 19
The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
Maria Carmen Valcarce Lopez, Eliot Ohlstein
Filed: 10 Apr 18